114 related articles for article (PubMed ID: 31452195)
1. Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma.
Passero FC; Ravi D; McDonald JT; Beheshti A; David KA; Evens AM
Br J Haematol; 2020 Jan; 188(2):295-308. PubMed ID: 31452195
[TBL] [Abstract][Full Text] [Related]
2. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.
Ravi D; Beheshti A; Abermil N; Passero F; Sharma J; Coyle M; Kritharis A; Kandela I; Hlatky L; Sitkovsky MV; Mazar A; Gartenhaus RB; Evens AM
Cancer Res; 2016 Jun; 76(11):3319-31. PubMed ID: 26988986
[TBL] [Abstract][Full Text] [Related]
3. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.
Ravi D; Bhalla S; Gartenhaus RB; Crombie J; Kandela I; Sharma J; Mazar A; Evens AM
Clin Cancer Res; 2014 Dec; 20(23):6023-33. PubMed ID: 25316819
[TBL] [Abstract][Full Text] [Related]
4. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
5. Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
Zullo KM; Guo Y; Cooke L; Jirau-Serrano X; Mangone M; Scotto L; Amengual JE; Mao Y; Nandakumar R; Cremers S; Duong J; Mahadevan D; O'Connor OA
Clin Cancer Res; 2015 Sep; 21(18):4097-109. PubMed ID: 25878331
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
[TBL] [Abstract][Full Text] [Related]
7. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
[TBL] [Abstract][Full Text] [Related]
8. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
To KK; Tong WS; Fu LW
Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
[TBL] [Abstract][Full Text] [Related]
9. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
[TBL] [Abstract][Full Text] [Related]
10. Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma.
Kong LR; Tan TZ; Ong WR; Bi C; Huynh H; Lee SC; Chng WJ; Eichhorn PJA; Goh BC
Mol Oncol; 2017 Aug; 11(8):965-980. PubMed ID: 28397399
[TBL] [Abstract][Full Text] [Related]
11. Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.
Havas AP; Rodrigues KB; Bhakta A; Demirjian JA; Hahn S; Tran J; Scavello M; Tula-Sanchez AA; Zeng Y; Schmelz M; Smith CL
Cancer Biol Ther; 2016 Dec; 17(12):1240-1252. PubMed ID: 27791595
[TBL] [Abstract][Full Text] [Related]
12. Ritonavir Interacts With Belinostat to Cause Endoplasmic Reticulum Stress and Histone Acetylation in Renal Cancer Cells.
Isono M; Sato A; Okubo K; Asano T; Asano T
Oncol Res; 2016; 24(5):327-335. PubMed ID: 27712589
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells.
Kewitz S; Bernig T; Staege MS
Leuk Res; 2012 Jun; 36(6):773-8. PubMed ID: 22424710
[TBL] [Abstract][Full Text] [Related]
14. A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.
Boonstra PS; Polk A; Brown N; Hristov AC; Bailey NG; Kaminski MS; Phillips T; Devata S; Mayer T; Wilcox RA
Am J Hematol; 2017 Dec; 92(12):1287-1294. PubMed ID: 28842936
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.
Valdez BC; Li Y; Murray D; Brammer JE; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
Oncotarget; 2016 Sep; 7(39):63829-63838. PubMed ID: 27564097
[TBL] [Abstract][Full Text] [Related]
16. Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer.
Finnegan E; Ding W; Ude Z; Terer S; McGivern T; Blümel AM; Kirwan G; Shao X; Genua F; Yin X; Kel A; Fattah S; Myer PA; Cryan SA; Prehn JHM; O'Connor DP; Brennan L; Yochum G; Marmion CJ; Das S
Cell Oncol (Dordr); 2024 Apr; 47(2):533-553. PubMed ID: 37934338
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase.
Kim MJ; Lee JS; Park SE; Yi HJ; Jeong IG; Kang JS; Yun J; Lee JY; Ro S; Lee JS; Choi EK; Hwang JJ; Kim CS
J Urol; 2015 May; 193(5):1660-8. PubMed ID: 25433307
[TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
Odenike O; Halpern A; Godley LA; Madzo J; Karrison T; Green M; Fulton N; Mattison RJ; Yee KW; Bennett M; Koval G; Malnassy G; Larson RA; Ratain MJ; Stock W
Invest New Drugs; 2015 Apr; 33(2):371-9. PubMed ID: 25483416
[TBL] [Abstract][Full Text] [Related]
19. A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.
Ong PS; Wang L; Chia DM; Seah JY; Kong LR; Thuya WL; Chinnathambi A; Lau JY; Wong AL; Yong WP; Yang D; Ho PC; Sethi G; Goh BC
Cancer Lett; 2016 Oct; 381(1):49-57. PubMed ID: 27461583
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapy for EBV-Associated B-cell Neoplasms.
Ganguly S; Kuravi S; Alleboina S; Mudduluru G; Jensen RA; McGuirk JP; Balusu R
Mol Cancer Res; 2019 Apr; 17(4):839-844. PubMed ID: 30487243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]